On February 16, 2017, the European Parliament passed the Comprehensive and Economic Trade Agreement (CETA). CETA is an EU-Canadian free trade agreement that plans to eliminate more than 90% of tariffs and was passed in a time of growing economic isolationism. It is interesting to examine CETA from an intellectual property perspective. One ground that CETA has been criticized on is that CETA will extend the terms of drug patents and critics argue this could cause drug prices to rise. This complaint is a microcosm of a more general concern with respect to intellectual property- that intellectual property provisions, in free trade agreements, frequently cause wealth concentration. It will be interesting to see if this prediction comes true or will the CETA stand true to its word to be a progressive treaty the benefits the middle class.